TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15503077

Group type: EXPERIMENTAL
Intervention: Total daily energy expenditure (TEE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resting metabolic rate (RMR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dietary intake
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Physical activity and body composition measurements
Number of subjects: 36
Study: 10709155

Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg intravenously (IV)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg subcutaneously (SC)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg IV
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg SC
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cetrorelix (CET) 3 mg IV and SC
Number of subjects: 11
Study: 9350465

Group type: EXPERIMENTAL
Intervention: Comprehensive NSI Prevention Program including policy and procedure revisions
Number of subjects: 0
Study: 1547881

Group type: EXPERIMENTAL
Intervention: Single-agent interferon (IFN)-alpha at an initial dose of 4 x 10(6) U/m2 (arm A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of IFN-alpha and low-dose IFN-gamma (arm B)
Number of subjects: 51
Study: 3988412

Group type: EXPERIMENTAL
Intervention: 1-min incremental cycle ergometer test
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3-min incremental cycle ergometer test
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5-min incremental cycle ergometer test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All tests (1, 3, and 5 min)
Number of subjects: 10
Study: 3299440

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 30953874

Group type: EXPERIMENTAL
Intervention: Social inclusion condition
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Social rejection condition
Number of subjects: 164
Study: 28586116

Group type: COMPARATOR
Intervention: Fecal microbiota transplant (FMT) with 5 days of broad-spectrum antibiotic pretreatment and a single FMT enema from the same donor.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone.
Number of subjects: 0
Study: 26715372

Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 131
Study: 23279966

Group type: EXPERIMENTAL
Intervention: Student mentors
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Peer mentors
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Peer mentors working independently of researchers
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 106
Study: 21997429

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 43
Study: 18444793

Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole plus 150 mg of fluconazole
Number of subjects: 310

Group type: COMPARATOR
Intervention: metronidazole placebo plus fluconazole placebo
Number of subjects: 310
Study: 16516541

Group type: EXPERIMENTAL
Intervention: Large electrode (36 x 36 mm)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Small electrode (6 x 6 mm)
Number of subjects: 14
Study: 14979636

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (200 mg for children ≤ 7 years, 290 mg for children > 7 years)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (260 mg glucose)
Number of subjects: 89
Study: 10907966

Group type: EXPERIMENTAL
Intervention: Argatroban (30, 60, 120, or 240 microg/kg bolus)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Heparin (30, 60, 120, or 240 U/kg bolus)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Argatroban (1.25, 2.5, 5, or 10 microg/kg/minute with or without a 250-microg/kg bolus)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Heparin (0.15, 0.20, 0.25, or 0.30 U/kg/minute with or without a 125-U/kg bolus)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Argatroban (250-microg/kg bolus plus infusion of 15, 20, 30, and 40 microg/kg/minute)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 82
Study: 8698954

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Naltrexone (opioid receptor blockade)
Number of subjects: 32
Study: 1580283

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4005391

Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg (repeated dose)
Number of subjects: 21
Study: 31087536

Group type: EXPERIMENTAL
Intervention: Fluconazole with a loading dose of 25 mg/kg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Fluconazole without specified loading dose
Number of subjects: 166
Study: 30336850

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg kg-1 then 4 mg kg-1 h-1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous lidocaine and saline
Number of subjects: 40
Study: 27615041

Group type: EXPERIMENTAL
Intervention: Exhalation breathing exercises using expirometer
Number of subjects: 63

Group type: COMPARATOR
Intervention: Inhalation breathing exercises using incentive spirometry (Control)
Number of subjects: 63
Study: 24979262

Group type: EXPERIMENTAL
Intervention: Endobronchial coiling
Number of subjects: 17
Study: 22309470

Group type: EXPERIMENTAL
Intervention: Contingency management in combination with family engagement strategies (CM-FAM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual services (US)
Number of subjects: 104
Study: 20542492

Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging (LSCI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Laser Doppler Flowmetry (LDF)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Laser Doppler Imaging (LDI)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry (LDF) and Laser Speckle Contrast Imaging (LSCI)
Number of subjects: 28
Study: 18563775

Group type: EXPERIMENTAL
Intervention: Long-pulsed dye laser (LPDL)
Number of subjects: 20
Study: 15734833

Group type: EXPERIMENTAL
Intervention: Moderately hypocaloric very-low-fat diet (3%)
Number of subjects: 8
Study: 12404080

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) patches (21 mg/24 h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Free smoking
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) patches
Number of subjects: 24
Study: 9454908

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g/day for three days)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 96
Study: 7897049

Group type: EXPERIMENTAL
Intervention: Schizotypy assessed by the Perceptual Aberration Scale (PAS)
Number of subjects: 1646

Group type: EXPERIMENTAL
Intervention: MAXCOV‐HITMAX taxometric analytic procedures
Number of subjects: 1646
Study: 1710743

Group type: EXPERIMENTAL
Intervention: Bezafibrate (Bezalip Mono) 400 mg once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 39200

Group type: EXPERIMENTAL
Intervention: Regulated-breathing method
Number of subjects: 21

Group type: COMPARATOR
Intervention: Abbreviated desensitization (placebo-control)
Number of subjects: 21
Study: 29743827

Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (CMR) with a 6% unflavored maltodextrin solution
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo mouth rinse (PMR)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Drinking 'ad libitum' (DAL)
Number of subjects: 11
Study: 26246020

Group type: EXPERIMENTAL
Intervention: Polysoft patch (PP)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Modified Kugel patch (MK)
Number of subjects: 442
Study: 24162751

Group type: EXPERIMENTAL
Intervention: Inserter device (EndoSerter; Ocular Systems Inc, Winston‐Salem, NC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sheet glide (Surgical Glide; Beaver‐Visitec International Inc, Waltham, MA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control grafts
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sheet glide (cases 6-10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EndoSerter (cases 6-10)
Number of subjects: 20
Study: 22892729

Group type: EXPERIMENTAL
Intervention: 1-visit treatment
Number of subjects: 282

Group type: COMPARATOR
Intervention: 2-visit treatment
Number of subjects: 282
Study: 21061502

Group type: EXPERIMENTAL
Intervention: Perspective taking of a third party
Number of subjects: 114

Group type: COMPARATOR
Intervention: Nonperspective taking
Number of subjects: 114
Study: 17627003

Group type: EXPERIMENTAL
Intervention: Self-referral group
Number of subjects: 268

Group type: COMPARATOR
Intervention: Population-based sampling group
Number of subjects: 268
Study: 15842552

Group type: EXPERIMENTAL
Intervention: Gentamicin delivered via Pari LC + nebulizer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gentamicin delivered via MicroNeb III nebulizer
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gentamicin delivered orally (80 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gentamicin delivered intravenously (40 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aerodynamic characteristics of nebulized doses from PARI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aerodynamic characteristics of nebulized doses from MN
Number of subjects: 10
Study: 11932273

Group type: EXPERIMENTAL
Intervention: E/A group (1.25 mg estrogen + 2.5 mg methyltestosterone/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E/A group
Number of subjects: 40

Group type: COMPARATOR
Intervention: E group (1.25 mg/d)
Number of subjects: 40
Study: 9577336

Group type: EXPERIMENTAL
Intervention: High fat meal (52% fat)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Balanced meal (24% fat)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients with reflux disease
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 27
Study: 8147328

Group type: EXPERIMENTAL
Intervention: 16:0-rich diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: 12:0 + 14:0-rich diet
Number of subjects: 17
Study: 3276201

Group type: EXPERIMENTAL
Intervention: 200 mg of estradiol valerate topical gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 mg of prostaglandin E2 gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo prostaglandin E2 dosage
Number of subjects: 40
Study: 28867130

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 0.5 mg bevacizumab
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional laser photoablation
Number of subjects: 21
Study: 27912207

Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERAs)
Number of subjects: 4894

Group type: COMPARATOR
Intervention: Bosentan
Number of subjects: 4894

Group type: COMPARATOR
Intervention: Macitentan
Number of subjects: 4894

Group type: COMPARATOR
Intervention: Ambrisentan
Number of subjects: 4894
Study: 26644132

Group type: EXPERIMENTAL
Intervention: Reinforcement‐based Treatment plus Women's Co‐Op (RBT + WC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Case Management (CM)
Number of subjects: 128
Study: 23162040

Group type: EXPERIMENTAL
Intervention: Cognitive treatment of illness perceptions
Number of subjects: 156

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 156
Study: 21533643

Group type: EXPERIMENTAL
Intervention: Arthroscopic repair (ASC) with double-row repair using resorbable anchors
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mini-open repair (MO) with transosseous repair
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both ASC and MO groups
Number of subjects: 34
Study: 18542921

Group type: EXPERIMENTAL
Intervention: High volume hemofiltration (HVHF 65 ml/(kg h))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low volume hemofiltration (LVHF 35 ml/(kg h))
Number of subjects: 20
Study: 16422722

Group type: EXPERIMENTAL
Intervention: Home support by nurse lactation consultants
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 138
Study: 12623632

Group type: EXPERIMENTAL
Intervention: Sincere performance condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insincere performance condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 0
Study: 11225967

Group type: EXPERIMENTAL
Intervention: Regular human insulin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 19
Study: 9537146

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with a van Lint block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retrobulbar block with a van Lint block
Number of subjects: 40
Study: 8000269

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with preservation of both leaflets
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard mitral valve replacement
Number of subjects: 7
Study: 3294407

Group type: EXPERIMENTAL
Intervention: Ticarcillin disodium/clavulanate potassium
Number of subjects: 133

Group type: COMPARATOR
Intervention: Clindamycin/gentamicin
Number of subjects: 133
Study: 31045229

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Valproic acid and Placebo
Number of subjects: 128
Study: 28555011

Group type: EXPERIMENTAL
Intervention: Lower fat diet (20% energy), higher carbohydrate diet (65% energy)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet (45% energy), higher fat diet (35% energy)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Walnut-rich diet (18% energy), higher fat diet (35% energy), lower carbohydrate diet (45% energy)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CC genotype
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 242
Study: 24646529

Group type: EXPERIMENTAL
Intervention: Half-day educational intervention with lectures, structured feedback, and debriefing
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 29
Study: 22353457

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants with tooth preparation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resin sealants with tooth preparation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants without tooth preparation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resin sealants without tooth preparation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resin sealants
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tooth preparation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealants without preparation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Caries development
Number of subjects: 25
Study: 20089776

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (0, 5, 10, and 15 microg cholecalciferol/d)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 18054638

Group type: EXPERIMENTAL
Intervention: PDT plus IVTA
Number of subjects: 30

Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 30
Study: 16076991

Group type: EXPERIMENTAL
Intervention: High dairy diet (1200 mg Ca/d, 3 servings of dairy)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low dairy diet (500 mg/d, <1 serving/d)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High dairy diet (1200 mg Ca/d, 3 servings of dairy) with caloric restriction (‐500 kcal/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low dairy diet (500 mg/d, <1 serving/d) with caloric restriction (‐500 kcal/d)
Number of subjects: 63
Study: 12242580

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.27 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10224181

Group type: EXPERIMENTAL
Intervention: Surfactant lavage with 15 mL/kg of diluted surfactant solution (Survanta) at a phospholipid concentration of 5 mg/mL administered in 2-mL aliquots
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Surfactant lavage
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study: 7925507

Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 11472

Group type: EXPERIMENTAL
Intervention: General population
Number of subjects: 11472

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 11472

Group type: COMPARATOR
Intervention: Diabetics
Number of subjects: 11472
Study: 2573757

Group type: EXPERIMENTAL
Intervention: Intensive monitoring (electronic fetal heart rate monitoring with scalp blood sampling when indicated)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intensive monitoring
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (intermittent intrapartum monitoring)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Total cases of cerebral palsy (both groups)
Number of subjects: 13
Study: 1096831

Group type: EXPERIMENTAL
Intervention: Added lactose formula
Number of subjects: 29

Group type: COMPARATOR
Intervention: Added sucrose formula
Number of subjects: 29
Study: 30770586

Group type: EXPERIMENTAL
Intervention: Map-CT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Eur-CT
Number of subjects: 96

Group type: COMPARATOR
Intervention: Map-CG
Number of subjects: 96

Group type: COMPARATOR
Intervention: Eur-CG
Number of subjects: 96
Study: 28181920

Group type: EXPERIMENTAL
Intervention: Early rehabilitation program
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard-care group (physical therapy as ordered by the primary care team)
Number of subjects: 53
Study: 26234174

Group type: EXPERIMENTAL
Intervention: vosaroxin plus cytarabine
Number of subjects: 711

Group type: COMPARATOR
Intervention: placebo plus cytarabine
Number of subjects: 711
Study: 23714773

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80‐mg loading dose given a mean of 1.5 hours before percutaneous coronary intervention)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 22120855

Group type: EXPERIMENTAL
Intervention: Eperisone 150 mg/day in three divided doses
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 19017422

Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: gelatin breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: gelatin+TRP breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: all diets
Number of subjects: 24
Study: 16790638

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 12760996

Group type: COMPARATOR
Intervention: Full-length circulating water mattress set at 42 degrees C
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lower-body forced-air cover with the blower set on high
Number of subjects: 24

Group type: COMPARATOR
Intervention: Three-extremity carbon-fiber resistive-heating blanket set to 42 degrees C
Number of subjects: 24
Study: 10672633

Group type: EXPERIMENTAL
Intervention: Alcohol (0.26-0.28 g.kg-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo drink
Number of subjects: 0
Study: 9232961

Group type: EXPERIMENTAL
Intervention: Electrical tooth stimulus (EP-TS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Electrical finger stimulus (EP-FS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Electrical tooth stimulus (EP-TS) and Electrical finger stimulus (EP-FS)
Number of subjects: 17
Study: 8469945

Group type: EXPERIMENTAL
Intervention: Inferential stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-frequency stimulation
Number of subjects: 20
Study: 2948929

Group type: EXPERIMENTAL
Intervention: 2.5% benzoyl peroxide
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 153

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide
Number of subjects: 153

Group type: COMPARATOR
Intervention: 10% benzoyl peroxide
Number of subjects: 153
Study: 30158423

Group type: EXPERIMENTAL
Intervention: TAS-102
Number of subjects: 2
Study: 26439816

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 345

Group type: COMPARATOR
Intervention: Diet-only
Number of subjects: 345
Study: 25208500

Group type: EXPERIMENTAL
Intervention: Anterior endoscopic release (AER) followed by posterior instrumentation and correction
Number of subjects: 56

Group type: COMPARATOR
Intervention: Posterior procedure without AER
Number of subjects: 56
Study: 22986437

Group type: EXPERIMENTAL
Intervention: Linaclotide 290 μg once daily
Number of subjects: 804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 804
Study: 20186437

Group type: EXPERIMENTAL
Intervention: 6 mg melatonin
Number of subjects: 52

Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 52
Study: 19086332

Group type: EXPERIMENTAL
Intervention: Alosetron treatment for 3 weeks
Number of subjects: 17
Study: 15708698

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959
Study: 12519139

Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric nerve block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Caudal epidural block
Number of subjects: 30
Study: 10471432

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 20